Sintx Technologies price target lowered to $7 from $22 at Maxim

Maxim analyst Tate Sullivan lowered the firm’s price target on Sintx Technologies to $7 from $22 but keeps a Buy rating on the shares. The analyst is citing share dilution after the company’s recently closed $12M public offering, though the firm also remains positive on opportunities in multiple markets – including dental implants, nuclear equipment coating work, hip and knee joint replacements, and various aerospace and industrial components – after Sintx announced that the company’s ceramic armor manufacturing facility is now fully operational.